Education:

  • 2019 Ph.D. Molecular Medicine module, Medical faculty, University of Belgrade
  • 2011 B.Sc. of Veterinary Medicine, Faculty of Veterinary Medicine, University of Belgrade

Research Experience:

  • 2020 Research Associate, Institute of pharmacology, clinical pharmacology, and toxicology, Medical faculty, University of Belgrade
  • 2014 Research Assistant, Institute of pharmacology, clinical pharmacology, and toxicology, Medical faculty, University of Belgrade
  • 2012 Research Trainee, Institute of pharmacology, clinical pharmacology, and toxicology, Medical faculty, University of Belgrade

Other activities:

  • 2023 Member of the Immunological Society of Serbia
  • 2021-2022 Engaged in the “ZEBARR” project of the IDEAS Fund for Science under the leadership of Dr. Snežana Kojić at the Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade
  • 2017-2019 Involved in a bilateral project between the Faculty of Medicine, University of Belgrade, and the Faculty of Medicine in Budapest. As part of this collaboration, visited the Budapest Faculty twice, each visit lasting for ten days.
  • 2014-2016 Participating in a two-year collaborative study with the University of Malaysia, focusing on a comparative examination of organotoxicity between pulverized and nanoparticle-conjugated doxorubicin.
  • 2013
    Involved as a lecturer in both the theoretical and practical aspects of the course “Experimental Methodology of Research in Medicine” during the winter semester of the doctoral academic studies at the Faculty of Medicine, University of Belgrade.
  • 2012-2019 Engaged in the project “BIOMEDICINE III: Functional genomics of the hypothalamus and medulla in hypertension induced by chronic stress” funded by the Ministry of Science of the Republic of Serbia, under the leadership of Prof. Nina Žigon at the Institute of Pharmacology, Clinical Pharmacology, and Toxicology, Faculty of Medicine, University of Belgrade.

Field of Scientific Interest:

  • Toxic cardiomyopathy induced by doxorubicin
  • Pathomorphology and pathohistology of toxic and degenerative conditions
Marko Vasic

Marko Vasic

Research Associate

Pre-clinical Studies & Immunology department Research and Science division

mvasic@torlak.rs